Skip to main content

Table 4 Changes in TRACP-5b levels during the study period

From: Clinical advantage and tolerability of ibandronate in hemodialysis patients: a retrospective study

Patient Sex Age (years) Baseline iPTH (pg/mL) Baseline serum calcium (mEq/L) Baseline BALP (μg/L) Baseline TRACP-5b (mU/dL) End of study TRACP-5b (mU/dL) Changing levels of TRACP-5b (mU/dL)
1 Female 80 69 8.5 12.6 1110 656 − 454
2 Male 68 279 9.4 15.5 656 754 + 98
3 Male 89 478 9.2 9.6 346 256 − 90
4 Male 57 246 8.8 12.1 641 584 − 57
5 Male 67 238 8.8 17.6 1070 946 − 124
6 Female 71 474 8.4 19.3 633 366 − 267
7 Male 92 280 8.2 11.5 933 684 − 249
8 Male 83 50 9.3 6.5 425 195 − 230
9 Male 78 42 8.6 9.7 301 179 − 122
10 Female 85 773 10.1 36.8 1400 1110 − 290
11 Female 88 167 8.4 31.9 986 558 − 428
12 Male 78 65 8.7 10.1 338 328 − 10
13 Male 79 542 8.1 41.6 1370 1680 + 310
  1. iPTH intact parathyroid hormone, TRACP-5b tartrate-resistant acid phosphatase-5b, BALP bone-specific alkaline phosphatase